Trump’s executive order halts an effort to cap the copayment for generic medications at $2 for Medicare beneficiaries.

The Biden administration announced on Friday the selection of the next 15 prescription drugs that will undergo price negotiations between manufacturers and Medicare, three days before President-elect Donald Trump is set to take office and take over the program.

Trump rescinded Executive Order 14087, "Lowering Prescription Drug Costs for Americans," which directed Medicare and Medicaid agencies to research and implement models for lowering the costs of prescription drugs. Separate provisions in the Inflation Reduction Act of 2022 also aimed at lower prescription drug costs are still in effect.

The Trump administration’s first drug pricing action — rescinding a Biden executive order encouraging Medicare to help lower prescription costs — is befuddling drug pricing experts.

One of those now-cancelled policies directed Medicare to investigate ways to slash drug costs, including the possibility of a $2 monthly out-of-pocket cap on some generic medications. Monday's actions also follow through on a key goal of Trump's first term -- weakening the Affordable Care Act.

As President Donald Trump’s health care agenda for a second term takes shape, it’s becoming clear that many Biden-era policies won’t make the cut.

Drug pricing experts are not sure why rolling back drug pricing initiatives would be a day one priority for President Trump.